[Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Shiozawa
Shunichi
S
Department of Surgery, Tokyo Women's Medical University Medical Center East.
Tsuchiya
Akira
A
Kim
Dal Ho
DH
Ogawa
Kenji
K
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D000093542:Gemcitabine